Biocity Biopharmaceutics
CompanyChina
Biocity Biopharmaceutics develops one asset, in phase 2 (SC0062 in type 1 diabetes mellitus with diabetic nephropathy). Mostly small molecule acting on EDNRA; based in China.
- 1
- Asset
- Furthest stage
- Phase 2
- 1
- Trial
- 1
- Signal
Pipeline
1Blocks endothelin A receptors to reduce endothelin-mediated renal injury.
Phase 2, Small molecule, EDNRA, type 1 diabetes mellitus with diabetic nephropathy
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials2
- Signals1
- Similar companies3